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Results:
The data recovered after the quality control of the IMRT plans for
prostate and H&N patients are present in figure 1. From the 89 H&N
plans evaluated 48 were approved in the first measurement, 32 were
rejected and only 9 plans were repeated. Regarding the prostate
patients, there were evaluated 52 plans, from which 28 were approved
in the first measurement, 17 were rejected and 7 were repeated.
Figure 2 represents the rejected plans in prostate and H&N tumours
associated with the rejection of the values of absolute dose and relative
dose. In H&N rejected plans 10 were due to the measurements of the
relative dose and 32 due to the absolute dose measurements.
Regarding the prostate plans 3 were rejected due to the relative dose
measurements and 17 due to the absolute dose measurements.
In table 1 we can see the descriptive statistics of the obtained data
regarding the quality control measurements of all the IMRT plans
studied.
By applying an hypothesis test to evaluate the proportion relations the
obtain results revel that the percentage of prostate and H&N approved
plans is significantly inferior to 1 (p=0,53 and p=0,54, respectively).
Using the mean and standard deviation values it was calculated the
variation coefficient for all the plans. For the rejected plans this
coefficient is 37,11%, for the repeated plans the coefficient is 43,29%
and for the approved plans the variation coefficient is 37,22%.
Methodology:
This is a retrospective study that includes all the quality controls of the
IMRT plans produced between March and December of 2011 at the
Hospital del Meixoeiro. The sample of this study is 141 quality control
measurements, 52 referring to prostate cancer IMRT plans and the
remaining 89 to H&N IMRT plans.
The equipment used in the IMRT quality controls was the MapCHECK®
commercialized by SunNuclear Corporation®. This system contains
diodes that detect the administrated dose, at the moment, by each
planned treatment field, and this equipment only requires an annual
calibration, as recommended by the manufacturer6,8.
The commissioning of the planning systems consists in the comparison
of the values measured at the linear accelerator with MapCHECK® and
the calculated dose distribution2-6,9-12. These measurements allow an
analysis of the planning through the graphical superposition of the
measured and planned dose3-11. Each measurement is made with the
gantry and the table with a rotation of 0º.
MapCHECK® uses the Gamma 3.3 (3%, 3mm) formula and takes into
account the dose-difference and the distance-to-agreement (DTA)3-6,9-12.
For areas with a low dose gradient the evaluated criteria is the dose-
difference that corresponds to the difference between the measured
dose and the planned dose, that can’t exceed 3%. In the regions with
high dose gradient it’s applied the DTA in which there is evaluated the
distance between the measured and the planned values that must be
lower than 3mm. When these criteria are not respected the plans can’t
be approved. It’s also evaluated the Gamma index, obtain by the
following formula:
Where Δdm corresponds to DTA and ΔDM to dose-difference9
The obtained measurements are presented as relative dose and
absolute dose. In the relative dose the treatment curve is superimposed
to the planned curve only from a common point. The absolute dose
compares all the measured points with all the planned points and, for
that, is the most important result. The dose plans are rejected whenever
the obtained values are lower than 95%, even if it’s in a single field13.
The results of this study where calculated by using frequencies and a
proportion statistical test, with resource to the software SPSS® v.20.
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Introduction:
Intensity Modulated Radiotherapy (IMRT) is a technique introduced to
shape more precisely the dose distributions to the tumour, providing a
higher dose escalation in the volume to irradiate and simultaneously
decreasing the dose in the organs at risk which consequently reduces
the treatment toxicity1-4. This technique is widely used in prostate and
head and neck (H&N) tumours4-6. Given the complexity and the use of
high doses in this technique it’s necessary to ensure a safe and secure
administration of the treatment, through the use of quality control
programmes for IMRT2,6-7.
The purpose of this study was to evaluate statistically the quality control
measurements that are made for the IMRT plans in prostate and H&N
patients, before the beginning of the treatment, analysing their
variations, the percentage of rejected and repeated measurements, the
average, standard deviations and the proportion relations.
Discussion/Conclusions:
All the IMRT treatments at Hospital do Meixoeiro are submitted to
quality control measurements. Regarding the period taken into account
in this study there were performed more IMRT treatment for H&N cancer
than for prostate cancer. Although all rejected plans should be repeated
we verified that only a few number of them are repeated.
Through the analysis of the data we observed that there is a high
number of rejection in the first measurement, and that in both groups the
values of the absolute dose were the motive for the rejection of the
plans. There is a higher variation in the values of the rejected plans and
a smaller variation in the values of the repeated plans.
There are some hypothesis that can explain the rejection of the plans:
the lack of sensitivity of the treatment planning system to take into
account the linear accelerator used; the fact that the beam segments
are very small or with shapes that are very difficult to reproduce with the
MLC; or because each beam segment has very few monitor units.
It’s important to study the causes by each the plans are rejected in order
to implement measures that improve the dosimetric studies and avoid a
high level of rejected plans during the quality control.
